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Abstract
A segment of the HIV infected population develops abnormal and excessive accumulation of
adipose tissue in the trunk, including accumulation of visceral (deep abdominal) adipose tissue. This
condition, known as HIV-related adipose redistribution syndrome (HARS), may also be
accompanied by fat accumulation in the upper back/neck (dorsocervical region) and/or depletion
of subcutaneous adipose tissue from the abdomen, face, limbs, or buttocks. HARS is estimated to
occur in up to 32% of patients and is associated with health risks similar to those of metabolic
syndrome. Techniques to detect and measure HARS include physician and patient assessments and
radiologic or anthropometric methods.
Background
Effective antiretroviral therapy has reduced AIDS
(acquired immune deficiency syndrome) mortality and
dramatically increased longevity to the point that the
long-term effects of HIV (human immunodeficiency
virus) infection and treatment are manifesting themselves
[1,2]. One particularly troublesome condition associated
with long-term treatment of HIV/AIDS is an alteration of
fat deposits in the body. In the late 1990s, reports of unu-
sual changes in body fat distribution in HIV patients
began to appear in the peer-reviewed literature [3-8].
Today, after almost a decade of study, the disturbance of
fat metabolism in HIV-infected patients remains inade-
quately understood and controversial [9-12]. Abnormal
accumulations of intra-abdominal fat [4,8,13-15],
enlarged dorsocervical fat masses [6,16-18], and fat loss
from the arms and legs, face, and buttocks [3,9,19-21] are
the most visible signs of metabolic disturbance in HIV-
infected patients with this syndrome. The term "lipodys-
trophy" is broad and is traditionally used to describe the
several morphologic changes related to fat distribution,
e.g. lipoatrophy (the loss of fat) and lipohypertrophy (fat
accumulation). Both lipoatrophy and lipohypertrophy
can occur separately or together in an individual.
In some HIV-infected patients, the body habitus changes
are characterized by increases in trunk fat, including accu-
mulation of visceral adipose tissue (VAT), which may
present as abdominal obesity or (more rarely) dorsocervi-
cal fat accumulation ("buffalo hump"). The term HIV-
associated adipose redistribution syndrome (HARS) has
been used to describe this syndrome [22-27], even though
it does not strictly represent "redistribution" of fat from
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patients may be accompanied by other metabolic distur-
bances including insulin resistance, glucose intolerance,
hypertension, and dyslipidemia, as well as by body image
distress [24,28-30]. HARS may also be accompanied by
lipoatrophy, typically involving loss of subcutaneous fat
of the face, arms, legs, and/or buttocks. Although the com-
bination of visceral adiposity and metabolic disturbances
is not unique to HIV, the pathogenesis and clinical pres-
entation appear to differ from those of "standard" obesity
in the general population.
In this review, we address the following topics regarding
central accumulation of fat in HIV-infected patients:
HARS characterization and case definition; health risks
associated with HARS; prevalence of HARS; signs of HARS
and its relationship to highly active antiretroviral therapy
(HAART), and HARS clinical presentation.
Lipohypertrophy and lipoatrophy: changing perspectives
Peripheral and central lipoatrophy affecting subcutaneous
fat is often associated with HIV infection [9,12,31].
Although central fat accumulation was noted in early
reports [5,7,16], appreciation of the clinical significance
of HIV-associated fat accumulation has come slowly in
studies of HIV-associated lipodystrophy.
There may be a number of reasons why fat accumulation
has received less attention than peripheral lipoatrophy in
the literature. Firstly, there appears to be a perception that
fat loss is more common than fat accumulation [9,32].
Secondly, patients may report fat loss more readily to their
physicians because of the undesirable cosmetic effects of
fat loss from the face, buttocks and extremities [33].
Thirdly, the presence of obesity may confound the detec-
tion of HIV-associated accumulation of fat [34]. Fourthly,
accumulation of VAT is not readily amenable to objective
measurement in the clinical setting [35,36], and sophisti-
cated imaging equipment is needed to visualize and spe-
cifically quantify HIV-associated accumulation of VAT
[36].
The 1998 Advisory Committee of the International Asso-
ciation of Physicians in AIDS Care (IAPAC) estimated that
approximately 1/3 of all treated HIV-infected patients
show evidence of intra-abdominal (visceral) fat accumu-
lation along with, or independent of, generalized obesity
[8]. This observation coincided with the introduction of
one of the first protease inhibitor (PI) drugs (indinavir)
that may have contributed significantly to lipodystrophy
with VAT accumulation [8]. In summary, HARS is a subset
of HIV-associated lipodystrophy in which there is abnor-
mal accumulation of trunk fat, including VAT, appearing
with or without concurrent lipoatrophy of subcutaneous
adipose tissue (SAT) in the limbs and face, or both.
Between 5% and 10% of HARS patients exhibit dorsocer-
vical fat accumulation [24].
To date, it has not been possible to bring the diverse
observations of altered fat distribution and metabolism
under the rubric of a single syndrome [32], and case defi-
nition remains a work in progress [37]. Without a clear
definition of what constitutes a "case" of HIV lipodystro-
phy, the field will continue to be plagued by a wide varia-
tion in prevalence estimates, uncertainty about risk factors
and indecision about proper course of treatment [38].
HARS case definition
Methodologic difficulties have plagued investigations of
HIV lipodystrophy. Differing case definitions, reliance on
detection methods with various levels of sensitivity and
specificity, and enrollment of different patient popula-
tions have made it difficult to compare results across stud-
ies. A low level of agreement between clinical and patient
assessments of fat redistribution has also contributed to
the problem of clarifying the case definition [39]. Finally,
the cross-sectional design of many studies is appropriate
for generating hypotheses about the possible association
of factors in lipodystrophy, but such studies cannot be
used to identify causal relationships.
To resolve these ambiguities, the HIV Lipodystrophy Case
Definition Study Group developed a statistical model for
the diagnosis of lipodystrophy (including age, sex, dura-
tion of HIV infection, HIV disease stage, waist-to-hip ratio
[WHR], anion gap, serum high-density lipoprotein-cho-
lesterol [HDL-C] concentration, trunk-to-peripheral fat
ratio, percentage leg fat, and intra- and extra-abdominal
fat ratio as variables) with a quantitative scale for detect-
ing cases [40,41]. The model efficiently captured cases of
HIV lipodystrophy (70% sensitivity, 80% specificity), but
this approach failed to develop a model specifically for
peripheral fat loss or central fat gain.
In fact, this case-definition exercise deliberately excluded
patients with moderate or severe "abdominal obesity"
without lipoatrophy on the assumption that it was "age-
related adiposity", and was thus biased against those with
central fat accumulation or HARS. Nevertheless, regional
fat accumulation was a prominent feature of the model
with high scores for fat accumulation on the dorsocervical
spine and abdominal region. There was no difference in
body mass index between the cases and the comparison
subjects (24.1 ± 3.7 vs 23.8 ± 3.8, P = 0.454). However, in
cases of lipodystrophy, WHR was greater (0.95 ± 0.09 vs
0.91 ± 0.07, P < 0.001), intra-abdominal fat was greater
(138 ± 88 cm2 versus 97 ± 71 cm2, P < 0.001), and the
ratio of intra-to-extra-abdominal fat was dramatically
greater (3.21 ± 9.87 vs 0.90 ± 1.16, P < 0.001) compared
with controls.Page 2 of 10
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In the Aquitaine Cohort (1999), in which 61% of the 581
patients were treated with PI, the overall incidence of fat
maldistribution was 38% [42]. Some form of peripheral
fat loss was observed in 90% of the patients, but 21% had
increased abdominal girth and 10% of the patients had
both peripheral fat loss and central fat accumulation. At
least one metabolic abnormality was seen in 54% of
patients; 51% of men and 45% of women had some form
of lipid or glucose abnormality. These results led the
authors of the Aquitaine study to suggest that there may
be 3 separate presentations of lipodystrophy – fat atrophy,
fat accumulation, and a mixed syndrome of both fat atro-
phy and accumulation [42].
A number of studies have consistently reported a signifi-
cant proportion of patients with central fat accumulation:
the Australian Prevalence Survey of Lipodystrophy Syn-
drome[43]the HIV Outpatient Study (HOPS) [44], the
LIPOCO Study [45], the Norwegian patient survey [46],
the Swiss cohort study [47], and the Australia cohort sur-
vey [43,48,49]. Safrin and Grunfeld (1999) surveyed
reports of localized fat accumulation and loss in HIV-
infected patients, and offered prevalence estimates of 1%
to 56% for fat accumulation, 1% to 24% for regional loss
of fat, and 2% to 83% for the pooled lipodystrophy syn-
dromes [10].
Lichtenstein et al. reviewed 15 published surveys with
>100 patients with descriptions suggestive of HARS [50].
They determined that prevalence estimates for HARS vary
widely, from 9% [51] to 48% [52] (mean 32%), depend-
ing on the criteria used for assessment: increased abdom-
inal girth, abdominal lipohypertrophy, abdominal
enlargement, central or abdominal fat accumulation,
truncal obesity, central fat gain, increased abdominal wall
thickness, or pseudo-obesity. From a review of published,
large cross-sectional and longitudinal studies, Tien and
Grunfeld determined similar estimates [12]; for any lipo-
dystrophy prevalence ranged from 30% to 62%, periph-
eral lipoatrophy from 22% to 38%, and any central fat
accumulation from 18% to 45%. The highest estimates in
the ranges reported by Tien and Grunfeld, however, all
came from one study, relying on physical examination
only and not on anthropometric or other objective meas-
urements [53].
Fat redistribution and metabolic changes in HIV infection 
study
The Fat Redistribution and Metabolic Changes in HIV
Infection Study (FRAM) was a large cross-sectional analy-
sis of 425 HIV-infected and 152 HIV-negative men, age 33
to 45, in which lipoatrophy or lipohypertrophy were
defined as concordance between subject report of the
direction of fat change and results of the physical exami-
nation [9,31]. The objective of this study was to compare
regional fat distribution (determined by self-report, phys-
ical examination and magnetic resonance imaging [MRI])
in HIV-positive men and population-based comparison
subjects. Whereas previous studies evaluated only the
presence of suspected changes, FRAM used bidirectional
instruments (increase or decrease, as well as scales) to
grade the magnitude of reported change as mild, moder-
ate or severe.
The FRAM study found no correlation between changes in
central fat and peripheral fat in HIV-infected men, meas-
ured either by self-report or physical examination [9,31].
In fact, the amount of central accumulation of fat was
equivalent in HIV-infected men and comparison men
without HIV, and peripheral fat loss did not necessarily
correlate with central fat loss. The study authors con-
cluded that central fat accumulation and peripheral fat
loss are not reciprocal processes; there is probably no
"relocation" of fat between these two depots.
The FRAM study results were somewhat controversial,
however. The researchers did not control for body mass
index and the HIV-negative control patients were signifi-
cantly heavier than the HIV-infected patients. This may
have contributed to the observation that increases in VAT
were more common in the control patients [54]. Further-
more, FRAM was a cross-sectional study; longitudinal
studies, such as ACTG 5005s (a substudy of ACTG 384),
have demonstrated an increase in truncal adiposity with
prolonged antiretroviral therapy [55]. In ACTG 5005s, the
prevalence of a high WHR increased from 35% at baseline
to 47% after 64 weeks of treatment with antiretrovirals.
This moderate relative change underscores the impor-
tance of knowing baseline values. However, unlike FRAM,
the ACTG studies did not include an HIV-negative control
group, so the extent to which the WHR compares with
age-matched HIV-negative controls is not clear.
The cross-sectional design of FRAM also does not shed
light on how quickly VAT might have accumulated after a
patient became infected with HIV or after initiating treat-
ment with HAART. Follow-up data from FRAM are
awaited with interest. With further study, perhaps the rate
of VAT accumulation may help distinguish HARS from
VAT accumulation related to general obesity.
Health risks associated with HARS
Physical symptoms associated with HARS primarily
include bodily discomfort due to local accumulation of a
large mass of VAT, with abdominal distension, respiratory
difficulty (similar to Pickwickian syndrome), umbilical
herniation, gastro-esophageal reflux, difficulty swallow-
ing, abdominal cramping, peptic ulcer, and constipation
or diarrhea [33]. It remains unknown if or how much thePage 3 of 10
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the effects of increased VAT.
VAT: independent predictor of all cause mortality
Visceral fat has been demonstrated as an independent pre-
dictor of all causes of mortality in a recent study of 291
non-HIV-infected men [56]. In the evaluation of all three
fat measures (subcutaneous, visceral and liver fat), age
and length of follow-up, only visceral fat was a significant
predictor of mortality in these non-HIV infected men
[56]. The derangements of fat metabolism and fat storage
seen in HARS may be similar to those seen in metabolic
syndrome [57] which, according to U.S. Cholesterol Edu-
cation Program Adult Treatment Panel III (ATP III), must
include three of the following five criteria: increased waist
circumference (>102 cm men, >88 cm women); increased
triglycerides (>150 ng/dL); reduced HDL-C (<40 mg/dL
men, <50 mg/dL women); high blood pressure (>130/
>85 mmHg); and elevated fasting glucose (>110 mg/dL)
[58].
This cluster of cardiovascular risk factors associated with
metabolic syndrome, and the prothrombotic state associ-
ated with them, may predispose HIV-infected patients
with HARS to premature cardiovascular disease [59].
Insulin resistance
VAT is an independent risk factor for insulin resistance
[60]. When Goodpaster et al. (1999) examined the effects
of weight loss on regional fat distribution and insulin sen-
sitivity in the general population with obesity, they found
that the reduction in VAT was the only adipose tissue
parameter that predicted the improvement in insulin sen-
sitivity [61].
An estimated 30% to 90% of patients receiving PI agents
are insulin resistant, although the incidence of diabetes
mellitus is less than 10% [62]. Lipodystrophy (peripheral
lipoatrophy and/or lipohypertrophy) is associated with
hyperinsulinemia and insulin resistance [13,63,64]. The
dorsocervical fat pad or "buffalo hump" has also been
associated with insulin resistance in an analysis of two
separate studies involving 1765 HIV-infected patients
[65]. In addition, impaired glucose tolerance is part of the
spectrum of metabolic changes seen in patients taking
antiretroviral therapy [29]. The direct effects of PI and
nucleoside reverse transcriptase inhibitor agents, and the
indirect effects of visceral adiposity and peripheral fat loss,
with fatty infiltration of muscle and liver, account in part
for the insulin resistance seen in the HIV-infected popula-
tion [66].
Cardiovascular risks
Cohort studies suggest that patients with HIV already face
an increased risk of acute myocardial infarction (MI) com-
pared with matched non-HIV-infected controls
[59,67,68]. In the subset of patients with HARS, the met-
abolic consequences of fat deposition may further
increase cardiovascular risk [59,68,69], although HIV
patients tend also to have high rates of other cardiovascu-
lar risk factors relative to age-matched HIV-negative indi-
viduals, including diabetes, hypertension and
dyslipidemia [67]. In addition, protease inhibitor use is a
strong predictor of MI in HIV-infected patients [70].
Waist-hip ratio and cardiovascular disease risk
WHR is an integrated index of body-composition changes
that reflects VAT stores. It is significantly related to cardio-
vascular disease risk in the general population [71] and
strongly predicts both fasting hyperinsulinemia and insu-
lin levels in both HIV-infected and -negative individuals
[28,72]. However, the extent to which WHR is a predictor
of cardiovascular disease in HIV has not yet been estab-
lished, especially since the WHR in HIV may be increased
by a low hip circumference (from lipoatrophy) in addi-
tion to an increased waist circumference.
A recent study investigated cardiovascular disease risk
indices in 100 consecutively recruited HIV-infected
women and 75 healthy female control subjects [28]. HIV-
infected women had more VAT and less extremity fat by
computerized tomography (CT) and dual-energy x-ray
absorptiometry (DXA) scan and demonstrated a higher
WHR than the control population. Among all subjects,
WHR, but not HIV status, was significantly related to high
levels of C-reactive protein and other cardiovascular dis-
ease risk indices. This could suggest that VAT (as indicated
by WHR) is accounting for most of the cardiovascular dis-
ease risk in both the HIV-positive and HIV-negative
cohorts. However, an earlier study found the coronary
heart disease risk estimate was greatest in HIV-infected
patients who had primary lipoatrophy, compared with
those who had either lipohypertrophy or mixed fat redis-
tribution [73].
The ACTG 362 study group found higher-than-normal
risk of cardiovascular disease among patients with
HAART-induced immune reconstitution, many of whom
had lipodystrophy [74]. The rate of atherosclerotic cardio-
vascular disease was 7.2 events per 1000 person-years (18
of 643 patients). These 18 patients experienced 20 athero-
sclerotic cardiovascular events (10 myocardial infarctions,
3 symptomatic coronary heart disease). Of 433 subjects
who agreed to remain in follow-up for evaluating risks of
cardiovascular disease and metabolic syndrome, 21% of
the men and 38% of the women had signs of metabolic
syndrome, 31% had a WHR 0.95 to 1.00, and 21% had
WHR >1.00.Page 4 of 10
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found the prevalence of metabolic syndrome was 14% by
International Diabetes Federation criteria and 18% by
ATP III [75]. Many of these patients (49%) had at least
two features of metabolic syndrome (particularly elevated
lipids) but did not meet the waist circumference or WHR
cutoff criteria for metabolic syndrome [75]. It may be that
the waist circumference and WHR criteria for the Interna-
tional Diabetes Federation and the ATP III definitions of
metabolic syndrome are set too high and are too insensi-
tive for maximal detection of cardiovascular and diabetic
risk in HIV-infected adults [76]. In various general popu-
lations and ethnic groups, the optimal criteria for identi-
fying high risk abdominally obese patients (with excess
VAT) remains unclear [77].
Systemic steatosis, e.g. hepatic and intramyocellular fat accumulation
Comorbid liver disease is common in patients with HIV,
and the presence of fatty liver may be caused and/or exac-
erbated by concomitant hepatitis virus infection, use of
certain antiretroviral drugs, chronic inflammation and
metabolic derangements [78].
Fatty liver, as well as VAT, in non-HIV individuals is
related to metabolic risk factors such as dyslipidemia,
insulin resistance and inflammatory markers [79,80].
Similarly, patients with HIV and dyslipidemia have
increased insulin resistance, and greater amounts of intra-
hepatic fat and VAT compared to HIV patients without
dyslipidemia or normal controls even when total body fat
mass is comparable [81]. The insulin resistance impairs
insulin from suppressing lipolysis of triglycerides in SAT
stores leading to increased release of free fatty acids. These
could contribute to expanded VAT stores, which in turn,
can release free fatty acids into the portal circulation
(Table 1). The increase in free fatty acids in the portal cir-
culation could lead to a net retention of lipid in the hepa-
tocytes or steatosis, which in turn could contribute to
systemic insulin resistance [81,82]. In addition, free fatty
acid oxidation stimulates gluconeogenesis and hepatic
glucose output and thus favors insulin resistance [83].
This is consistent with data showing that, in patients with
HIV lipodystrophy, the severity of insulin resistance is
related to the accumulation of fat in the liver rather than
to the accumulation of intra-abdominal fat [84].
Excess systemic free fatty acids can also find their way to
other tissues. Luzi et al. found that triglyceride levels
within the myocytes of the soleus and tibialis anterior
muscles were significantly elevated in HIV-positive
patients compared with healthy controls [85]. This
increased accumulation of fat in skeletal muscle of
patients with HIV and lipodystrophy is associated with
insulin resistance; there was an inverse relationship
between insulin action and intramyocellular lipid con-
tent.
Psychosocial effects of HARS
Patient-reported health-related quality-of-life issues asso-
ciated with abnormal fat distribution in HIV-positive
patients came to the attention of investigators early [86].
Changes in body shape stigmatize patients [87] and may
interfere with treatment adherence [88]. In addition,
patients' anxieties regarding long-term skeletal and cardi-
ovascular risks can interfere with treatment decisions [89].
Although it is difficult to isolate the effect of body habitus
changes alone on quality of life in HIV patients [90], sig-
nificant body image distress is associated with adipose tis-
sue maldistribution [30].
Signs of HARS
Patients with HARS tend to exhibit excess visceral adipos-
ity without increased total body fat, and have more VAT
than non-obese HIV-negative people with similar height-
adjusted weight [91]. Patients exhibiting signs of HARS
also may have a higher WHR, trunk-to-limb fat ratio, and
VAT/SAT ratio [36] than would be expected from their
body mass index [92]. HIV-infected patients with truncal
enlargement had 2.5–4 times more VAT on MRI scan [4]
and 4 times more VAT on single-slice CT scan than healthy
control subjects of similar age, sex and height. Engelson
and colleagues found that VAT volumes could be quite
large in HARS patients, and ranged from 2.1–9.8 L in HIV-
positive men with truncal obesity compared with 0.3–1.7
L (P < 0.001) in HIV-positive comparison patients with-
out truncal enlargement [4]. Men with truncal enlarge-
ment had 6.5 times more VAT than men without truncal
enlargement [4].
Extra-abdominal fat accumulation
HARS patients may also exhibit fat accumulation at extra-
abdominal sites (e.g. "buffalo hump") [6], and patients
exhibiting excess dorsocervical fat are likely to have
abnormal truncal fat accumulation as well [18,65]. In an
analysis of data from two cross-sectional cohort studies of
patients with HIV-associated lipodystrophy, all of the
patients with "buffalo hump" also reported central fat
accumulation, and 97% to 100% reported facial or but-
tock lipoatrophy [65]. In multivariate analysis, blood
pressure and insulin levels were both significantly associ-
ated with the presence of a buffalo hump (P ≤ 0.007), as
was duration of ritonavir (P = 0.004) or zidovudine (P =
0.005) use. This particular form of fat accumulation is
often very troublesome for patients, who may develop
sleep difficulties, snoring or sleep apnea [93], as well as
limited range of upper extremity and neck motion, neck
and back discomfort [93,94]. In addition to buffalo
hump, patients may also develop lipomas, which they
often find disfiguring [93].Page 5 of 10
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with HIV, the prevalence of suprapubic lipomas was
9.4%, but these lipomas were more common in patients
with dorsocervical fat deposition (18.5%), suggesting a
common pathogenesis between these two entities [95].
Other risk factors for pubic lipomas were female gender,
obesity (body mass index ≥ 30) and shorter duration of
HIV infection.
Detection of HARS
Body measurement of patients with fat redistribution syn-
drome is fraught with difficulties [96-99]. Studies of HIV
lipodystrophy have relied on several different means of
detecting and measuring changes in body shape: self-
report by means of questionnaires, scales for tabulating
clinicians' observations on physical examination, anthro-
pometric formulas, and radiographic techniques. Self-
report and questionnaires are open to subjective bias. In
general, levels of agreement (tested by kappa statistic)
between subjective measures have been poor [39].
Because HARS is marked by depots of VAT rather than
SAT, the condition may not always be evident on inspec-
tion or physical examination. In patients with mixed lipo-
dystrophy, the decrease in truncal SAT (lipoatrophy) may
contribute to a smaller than expected increase in waist cir-
cumference or WHR and thus lead to underestimation of
the amount of VAT [100]. The 4-year Multicenter AIDS
Cohort Study (MACS) suggested that, in at least some
HAART recipients, an increase in WHR could be attributed
to a relatively lower increase in hip circumference rather
than an increased rate of change in waist circumference
[101]. Visual inspection on physical exam in some HARS
patients may reveal abdominal distension as VAT pushes
the abdominal musculature forward [102]. In these, there
may be a lack of flabbiness or pinchable subcutaneous fat
stretched over a taut abdomen. However, other HARS
patients may present with large bellies that are difficult to
differentiate from general obesity.
Standard anthropometric tests have the advantage of
being readily available to clinicians [103,104]. Anthropo-
metric criteria, based on waist circumference and/or
WHR, have been used to estimate the relative mass of vis-
ceral fat [24,105,106]. Some studies have applied a com-
posite criterion of waist circumference >88 cm and WHR
≥ 0.95 for men, plus waist circumference >75 and WHR ≥
0.90 for women to effectively detect HIV-infected patients
with high VAT content [24,35,107,108]. These cutoffs for
WHR were based on published anthropometric criteria
considered to define visceral adiposity and increased car-
diovascular risk in adults [106,109]. As mentioned earlier,
WHR data may be misleading, especially if a patient has a
normal waist but massive loss of fat and muscle from the
hips and buttocks. Thus, in order to exclude patients with
apparently high WHR due to such dramatically reduced
hip circumference, a minimum waist circumference >88.2
cm was set for males and >75.3 cm for females [24]. While
these criteria should be subjected to independent valida-
tion, it has been suggested that they may be conservative
[108].
The most sensitive and specific methods for the detection
of VAT are CT scan and MRI because they provide quanti-
fiable data on the location and mass of visceral fat and
SAT [110]. DXA is sensitive and produces results within
Table 1: Functions of visceral adipose tissue compared with subcutaneous adipose tissue.
Visceral Adipose Tissue Subcutaneous Adipose Tissue
Major predictor of insulin resistance Preadipocytes have greater differentiation 
capacity
Associated with metabolic syndrome Unclear association with metabolic syndrome
Less responsive to adipogenic effects of insulin
Portal drainage
May enhance lipolysis of truncal subcutaneous adipose tissue May replenish visceral adipose tissue
Produces more interleukin-6 Produces leptin
Produces more plasminogen activator-1
More surface glucocorticoid receptors
High density of surface androgen receptors, inhibit expression of lipoprotein lipase and fatty 
acid uptake
Estrogen promotes accumulation
Altered glucose uptake Less glucose uptake
Enzyme 11-β hydroxysteroid dehydrogenase type 1 (11-β HSD1) converts cortisone to 
cortisol
Enzyme 11-β HSD1 barely detectable
Associated with impaired skeletal muscle fat oxidation
Associated with atherosclerosis May protect against atherosclerosis
Adapted from Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling 
dietary carbohydrates: a review. Nutr Metab (Lond). 2004;1(1):12. [13]Page 6 of 10
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of the appendages (SAT), but is more difficult for estima-
tion of VAT since changes in SAT and VAT independently
affect the mass of truncal fat [111]. Limitations of these
methods include: expense and limited availability; radia-
tion exposure associated with CT scan, limit to single-slice
and not whole-body studies; few data exist on normal dis-
tribution of VAT and SAT, so it is difficult to make com-
parisons; subcompartments of SAT and VAT are not
homogeneous, so whole-body estimates may be simplis-
tic.
Useful as these radiologic techniques are, CT, MRI and
DXA instruments are too expensive to be practical for the
identification of HARS patients in routine clinical prac-
tice. Routine measurement of waist circumference and/or
WHR may be helpful and are recommended for all
patients as it enhances diagnostic sensitivity for cardiovas-
cular risk factors [112].
Conclusion
Body habitus changes resulting from either lipoatrophy or
lipohypertrophy, or both, have been combined under a
single syndrome known as lipodystrophy. HARS is a spe-
cific form of HIV-associated lipodystrophy characterized
by abnormal accumulation of trunk fat, including VAT,
and may appear with or without concurrent lipoatrophy
of SAT. The best current prevalence estimate for HARS is
up to 32% of HIV-infected patients. In addition to disfig-
uring the patient's appearance (enlarged abdomen, "buf-
falo hump," perhaps exacerbated by peripheral
lipoatrophy), HARS is associated with metabolic disor-
ders and health risk factors similar to those of metabolic
syndrome. A more precise definition of HARS will require
a consensus statement inclusive of clinical manifestations
and symptoms. Further research in this area is necessary to
understand this complex condition.
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